Switzerland approves vaccine that targets two Covid variants
Moderna's new Covid-19 vaccine has been given temporary approval in Switzerland.
Copyright 2022 The Associated Press. All Rights Reserved
The Swiss medicaments regulator Swissmedic has given temporary approval for a Covid-19 vaccine from Moderna that has been adapted to give protection against two different strains of the virus.
This content was published on
1 minute
swissinfo.ch/mga
Español
es
Suiza aprueba vacuna contra dos variantes de COVID
The ‘Spikevax Bivalent Original/Omicron’ is designed to be administered in two 0.5ml doses.
It contains 25 micrograms of the original Spikevax mRNA-1273 plus 25 micrograms of a different mRNA that targets the Omicron variant (BA.1 and BA.4/5).
On Monday, Swissmedic saidExternal link that in trials the dual vaccine had achieved higher antibody concentrations against the Omicron variant than the original Spikevax, “with comparable side-effects”.
Those side-effects can include irritation, redness or swelling at the injection site, fatigue, headache, chills or nausea.
The Human Medicines Expert Committee has also given its separate seal of approval for the new vaccine, said Swissmedic.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Is reforming the Swiss pension system still possible, and if so, how?
Solutions still need to be found to meet the challenge of an ageing population and to improve the pensions of low-paid workers, the majority of whom are women.
This content was published on
The suspension of asylum procedures decided Monday following the fall of Bashar al-Assad affects 500 Syrian applicants in Switzerland.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland gives green light to Moderna’s Covid vaccine for 6-11 year olds
This content was published on
The Swiss medical regulator Swissmedic has approved Moderna’s Spikevax Covid-19 vaccine for use by children aged 6 to 11 years.
Switzerland approves its first protein-based Covid vaccine
This content was published on
The Swiss medical regulator has approved the Nuvaxovid vaccine for adults making it the fourth Covid-19 vaccine authorised in the country.
Too many Covid doses: Switzerland’s vaccine conundrum
This content was published on
Switzerland is sitting on around 38 million excess Covid-19 vaccine doses to be used by the end of 2022. What will it do with them?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.